Nuwellis Q3 operating loss narrows on margin gains, lower expenses

Overview

• US medical technology firm's Q3 net sales were flat yr/yr, impacted by prior-year backorder fulfillment

• Q3 operating loss narrowed 24% yr/yr, driven by gross margin expansion and lower expenses

• Pediatric segment Q3 sales rose 20% yr/yr, supporting overall business momentum

Outlook

• Nuwellis expects expanded Aquadex indication could increase adoption if FDA clearance is obtained

• Company says recent distribution agreements broaden product offering through existing commercial infrastructure

• Company did not provide specific financial guidance for the current quarter or full year

Result Drivers

• PEDIATRIC SEGMENT - Co said pediatric segment sales rose 20% yr/yr, supporting business momentum

• GROSS MARGIN EXPANSION - Co attributed higher gross margin to increased average selling prices and benefits from contract manufacturing

• COST MANAGEMENT - Operating expenses fell 13% yr/yr, reflecting expense management and operational efficiencies

Company press release:

Key Details

Reuters Recommended Reads

• Nov 10 - Airway clearance device maker Electromed's Q1 revenue rises on homecare growth

• Nov 9 - Hyperfine Q3 revenue jumps on higher system sales; net loss narrows

• Nov 10 - Surgical robotics firm Stereotaxis' Q3 revenue rises, but misses estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)